ReviewTrends in molecular medicine2012
New and future immunomodulatory therapy in type 1 diabetes.
Review in Trends in molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Human plasma-derived alphaPediatric diabetes · 2021Trial
- Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation.Journal of diabetes research · 2024Review
- Cutting-edge biotechnological advancement in islet delivery using pancreatic and cellular approaches.Future science OA · 2020Review
- Chloroquine as a promising adjuvant therapy for type 1 Diabetes Mellitus.Scientific reports · 2020Article
- Development and Characterization of a Preclinical Model for the Evaluation of CD205-Mediated Antigen Delivery Therapeutics in Type 1 Diabetes.ImmunoHorizons · 2019Article
- Increased β-cell proliferation before immune cell invasion prevents progression of type 1 diabetes.Nature metabolism · 2019Article
- Current Status on Immunological Therapies for Type 1 Diabetes Mellitus.Current diabetes reports · 2019Review
- Effects of TRPM7/miR-34a Gene Silencing on Spatial Cognitive Function and Hippocampal Neurogenesis in Mice with Type 1 Diabetes Mellitus.Molecular neurobiology · 2018Article
- Active Subjects With Autoimmune Type 1 Diabetes Have Better Metabolic Profiles Than Sedentary Controls.Cell transplantation · 2017Article
- Mesenchymal Stem and Progenitor Cells in Regeneration: Tissue Specificity and Regenerative Potential.Stem cells international · 2017Review
- Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets.F1000Research · 2016Review
- Endocrinology research-reflecting on the past decade and looking to the next.Nature reviews. Endocrinology · 2015Review
- Association of the interleukin-18 -137 C/G, -607 A/C polymorphisms with type 1 diabetes: A meta-analysis.Biomedical reports · 2014Article
- Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis).Transactions of the American Ophthalmological Society · 2014Article
- Islet inflammation: a unifying target for diabetes treatment?Trends in endocrinology and metabolism: TEM · 2013Review
- Stem cell therapy to cure type 1 diabetes: from hype to hope.Stem cells translational medicine · 2013Review
- Diabetes and beta cell function: from mechanisms to evaluation and clinical implications.Biochemia medica · 2013Review
- IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes.PloS one · 2013Article
- The Missing Heritability in T1D and Potential New Targets for Prevention.Journal of diabetes research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Type 1 diabetes is a common autoimmune disease that affects millions of people worldwide and has an incidence that is increasing at a striking rate, especially in young children. It results from the targeted self-destruction of the insulin-secreting β cells of the pancreas and requires lifelong insulin treatment. The effects of chronic hyperglycemia - the result of insulin deficiency - include secondary endorgan complications. Over the past two decades our increased understanding of the pathogenesis of this disease has led to the development of new immunomodulatory treatments. None have yet received regulatory approval, but this report highlights recent progress in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.